Hartford Financial Management Inc. buys 125 shares of Johnson & Johnson (NYSE: JNJ)


Hartford Financial Management Inc. increased its position in Johnson & Johnson (NYSE:JNJGet an assessment) by 0.4% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund held 33,223 shares of the company after acquiring an additional 125 shares during the period. Johnson & Johnson accounts for 1.4% of Hartford Financial Management Inc.’s portfolio, making the stock its 13th-highest position. Hartford Financial Management Inc.’s holdings in Johnson & Johnson were worth $5,888,000 at the end of the most recent period.

Other hedge funds have also increased or reduced their stakes in the company. Patron Partners LLC increased its position in Johnson & Johnson shares by 12.7% during the first quarter. Patron Partners LLC now owns 6,625 shares of the company worth $1,174,000 after purchasing an additional 747 shares during the period. Tandem Investment Advisors Inc. raised its position in Johnson & Johnson by 4.8% in Q1. Tandem Investment Advisors Inc. now owns 326,505 shares of the company valued at $57,867,000 after purchasing an additional 15,003 shares in the last quarter. Argent Advisors Inc. raised its position in Johnson & Johnson by 6.6% in the first quarter. Argent Advisors Inc. now owns 19,772 shares of the company valued at $3,504,000 after purchasing an additional 1,218 shares in the last quarter. Exeter Financial LLC increased its position in Johnson & Johnson by 3.2% in the 1st quarter. Exeter Financial LLC now owns 26,431 shares of the company valued at $4,684,000 after buying 819 additional shares in the last quarter. Finally, Fusion Capital LLC increased its position in Johnson & Johnson by 7.8% in the 1st quarter. Fusion Capital LLC now owns 27,844 shares of the company valued at $4,935,000 after purchasing an additional 2,019 shares in the last quarter. Institutional investors hold 68.78% of the company’s shares.

Analysts set new price targets

JNJ has been the subject of a number of recent research reports. Citigroup lowered its price target on Johnson & Johnson from $205.00 to $201.00 in a Wednesday, July 20 research report. Raymond James raised his price target on Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a Wednesday, April 20 research report. Morgan Stanley raised its price target on Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a Friday, July 8 research report. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong buy” rating in a Tuesday, May 17 research report. Finally, SVB Leerink lowered its price target on Johnson & Johnson from $200.00 to $194.00 in a Wednesday, July 20 research report. Four research analysts gave the stock a hold rating, five gave the company a buy rating and one gave the company a high buy rating. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $189.89.

Johnson & Johnson Stock Performance

Shares of NYSEJNJ opened at $170.18 on Wednesday. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt ratio of 0.37. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The stock has a 50-day moving average of $174.81 and a 200-day moving average of $174.68. The company has a market capitalization of $447.43 billion, a P/E ratio of 24.77, a P/E/G ratio of 3.25 and a beta of 0.59.

Johnson & Johnson (NYSE:JNJGet an assessment) last released its results on Tuesday, July 19. The company reported EPS of $2.59 for the quarter, beating the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The company posted revenue of $24.02 billion in the quarter, versus a consensus estimate of $23.85 billion. During the same period a year earlier, the company posted EPS of $2.48. The company’s revenue for the quarter increased 3.0% compared to the same quarter last year. As a group, equity research analysts expect Johnson & Johnson to post EPS of 10.05 for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 6. Shareholders of record on Tuesday, August 23 will receive a dividend of $1.13 per share. The ex-dividend date is Monday, August 22. This represents an annualized dividend of $4.52 and a dividend yield of 2.66%. Johnson & Johnson’s dividend payout ratio is currently 65.79%.

Insider Trading at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 40,000 shares of the company in a trade on Friday, June 10. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the sale, the executive vice president now directly owns 71,311 shares of the company, valued at approximately $12,336,803. The transaction was disclosed in a filing with the Securities & Exchange Commission, accessible via the SEC website. Separately, Executive Vice President Kathryn E. Wengel sold 40,000 shares of the company in a trade on Friday, June 10. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the sale, the executive vice president now directly owns 71,311 shares of the company, valued at approximately $12,336,803. The transaction was disclosed in a filing with the Securities & Exchange Commission, accessible via the SEC website. Also, CAD Robert J. Decker sold 8,462 shares of the company in a trade on Thursday, May 26. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the sale, the chief accounting officer now owns 15,473 shares of the company, valued at $2,785,140. Disclosure of this sale can be found here. 0.35% of the shares are currently held by company insiders.

Johnson & Johnson Company Profile

(Get an assessment)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells various healthcare products worldwide. The Company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the brands AVEENO, CLEAN & CLEAR, DR.

Recommended Stories

Institutional ownership by quarter for Johnson & Johnson (NYSE: JNJ)



Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily newsletter.